查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1492645

慢性頑固性咳嗽市場：按藥物類型、分銷管道分類 - 全球預測 2024-2030

Chronic Refractory Cough Market by Drug Type (Amitriptyline, Gabapentin, Pregabalin), Distribution Channel (Drug Store, Hospital Pharmacies, Online Pharmacies) - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

慢性頑固性咳嗽市場規模預計2023年為55.7億美元，預計2024年將達到58.8億美元，2030年將達到83.2億美元，複合年成長率為5.88%。

慢性難治性咳嗽 (CRC) 市場包括解決對傳統治療超過八週沒有反應的持續性咳嗽。氣喘、慢性阻塞性肺病和支氣管炎等慢性呼吸道疾病的增加自然會導致慢性頑固性咳嗽病例的增加。醫療基礎設施的改善和對結直腸癌認知的提高正在增加尋求慢性咳嗽治療的人數，從而擴大了市場。創新的治療方法和醫療技術的進步帶來了 CRC 的高效治療和管理，也是市場的重要成長動力。然而，由於大腸直腸癌的症狀與其他輕微疾病相似，因此經常被誤診或忽視，從而阻礙有效的治療。目前可用的一些治療方法具有顯著的副作用，這可能會阻礙患者並挑戰他們繼續接受處方治療的能力。此外，透過開發專為大腸直腸癌管理設計的新藥物配方和先進治療設備，還有巨大的成長機會。將 CRC 管理與遠端醫療平台結合可以增加患有這種疾病的患者的可近性，並促進持續管理，而無需頻繁去醫院。

主要市場統計
基準年[2023] 55.7億美元
預測年份 [2024] 58.8億美元
預測年份 [2030] 83.2億美元
複合年成長率（%） 5.88%

區域洞察

在美洲，美國和加拿大憑藉著先進的醫療基礎設施和對呼吸道疾病的高度意識層級，在慢性頑固性咳嗽治療市場中佔據主要地位。美國最近的專利趨勢集中在新型咳嗽藥物和咳嗽管理設備上，凸顯了治療中技術整合的趨勢。歐盟市場受到嚴格法規的指導，對有效和安全治療的需求不斷成長。歐盟消費行為的特徵是偏好實證治療方法。中東地區對包括大腸癌在內的慢性病的認知和醫療支出正在增加。中東地區對專業醫療服務和先進治療方法的國際合作越來越感興趣。非洲地區最近旨在改善醫療基礎設施和可近性的舉措可能會增加對 CRC 管理解決方案的長期需求。在亞太地區，中國的醫療基礎設施得到了快速改善，包括慢性咳嗽的治療。日本的結直腸癌治療通常使用政府醫療政策支持的最尖端科技和藥物。由於人口老化，日本也是 CRC 管理解決方案的重要市場。在印度，不斷壯大的中產階級和不斷改善的醫療設施正在為 CRC 管理創造巨大的商機。

FPNV定位矩陣

FPNV 定位矩陣對於評估供應商在慢性難治性咳嗽市場的定位至關重要。此矩陣提供了對供應商的全面評估，並檢查了與商務策略和產品滿意度相關的關鍵指標。這種詳細的評估使用戶能夠根據自己的要求做出明智的決定。根據評估結果，供應商被分為代表其成功程度的四個像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市場佔有率分析

市場佔有率分析是一種綜合工具，可以對慢性頑固性咳嗽市場供應商的現狀進行深入而詳細的評估。透過仔細比較和分析供應商的貢獻，您可以更深入地了解每個供應商的績效以及他們在爭奪市場佔有率時面臨的挑戰。這些貢獻包括整體收益、客戶群和其他重要指標。此外，該分析還提供了對該行業競爭性質的寶貴見解，包括在研究基準年期間觀察到的累積、分散主導地位和合併特徵等因素。有了這些詳細資訊，供應商可以做出更明智的決策並製定有效的策略，以在市場競爭中保持領先地位。

策略分析與建議

策略分析對於尋求在全球市場站穩腳跟的組織至關重要。對目前在慢性頑固性咳嗽市場中的地位進行全面評估，使公司能夠做出符合其長期願望的明智決策。此關鍵評估涉及對組織的資源、能力和整體績效進行徹底分析，以確定核心優勢和需要改進的領域。

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 慢性頑固性咳嗽盛行率普及
      • 政府對認知和早期診斷的支持
    • 抑制因素
      • 藥品召回的潛在風險
    • 機會
      • 加強有效藥物開發的研究和開發工作
      • 協作藥物開發和降低醫療成本
    • 任務
      • CRC 治療相關的副作用
  • 市場區隔分析
    • 藥物類型：探索Gabapentin作為治療神經病變相關慢性頑固性咳嗽的創新療法
    • 通路：慢性頑固性咳嗽網路藥局越來越受歡迎
  • 市場擾動分析
  • 波特五力分析
  • 價值鍊和關鍵路徑分析
  • 價格分析
  • 技術分析
  • 專利分析
  • 貿易分析
  • 法規結構分析

第6章 慢性難治性咳嗽市場藥物按類型

  • 阿米替林
  • Gabapentin
  • Pregabalin

第7章慢性頑固性咳嗽市場：依通路分類

  • 藥局
  • 醫院藥房
  • 網路藥房

第8章 北美和南美慢性難治性咳嗽市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第9章亞太地區慢性頑固性咳嗽市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第10章 歐洲、中東和非洲慢性難治性咳嗽市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第11章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • 呼吸治療新藥投資快速增加：Notion Therapeutics開發tupulcanium聚焦慢性頑固咳嗽
    • Trevi Therapeutics 與 Haduvio 開始 2a 期 RIVER 試驗，推進難治性慢性咳嗽的治療
    • GSK PLC 完成對 BELLUS Health Inc. 的收購，增強慢性難治性咳嗽治療產品組合
  • 戰略分析和建議

第12章競爭產品組合

  • 主要企業簡介
  • 主要產品系列
Product Code: MRR-9A2BA9536664

[182 Pages Report] The Chronic Refractory Cough Market size was estimated at USD 5.57 billion in 2023 and expected to reach USD 5.88 billion in 2024, at a CAGR 5.88% to reach USD 8.32 billion by 2030.

The Chronic Refractory Cough (CRC) market involves addressing a persistent cough that remains unresponsive to traditional treatments for more than eight weeks. Rising incidences of chronic respiratory conditions such as asthma, COPD, and bronchitis naturally lead to an increase in cases of chronic refractory coughs. Improved healthcare infrastructure and heightened awareness about CRC have led more individuals to seek treatment for chronic coughs, thus expanding the market. Innovative therapeutic approaches and advancements in medical technologies that offer higher efficacy in treating or managing CRC are also critical growth drivers in the market. However, CRC can often be misdiagnosed or overlooked as its symptoms may resemble those of other less severe illnesses, which can impede effective treatment. Some current treatments available have significant side effects, which might deter patients, creating challenges for continuing with their prescribed therapies. Moreover, there is a substantial opportunity for growth through the development of new pharmaceutical formulations and advanced therapeutic devices designed specifically for CRC management. Integrating CRC management with telehealth platforms can enhance accessibility for patients struggling with this condition, facilitating continuous management without frequent hospital visits.

KEY MARKET STATISTICS
Base Year [2023] USD 5.57 billion
Estimated Year [2024] USD 5.88 billion
Forecast Year [2030] USD 8.32 billion
CAGR (%) 5.88%

Regional Insights

In the Americas region, the U.S. and Canada represent a substantial market for the management of chronic refractory cough due to its advanced healthcare infrastructure and high awareness levels regarding respiratory conditions. Recent patents in the U.S. have focused on novel cough suppressant therapies and cough management devices, highlighting a trend toward technological integration in treatment. The EU market is guided by stringent regulations that drive the demand for highly effective and safe treatments. Consumer behavior in the EU is characterized by a preference for evidence-based therapies. In the Middle East, there is increasing awareness and healthcare expenditure concerning chronic diseases, including CRC. The Middle East region shows growing interest in specialized healthcare services and international collaborations for advanced treatment methods. Recent initiatives in the African region aim to improve healthcare infrastructure and accessibility, which may increase the demand for CRC management solutions in the long term. In the APAC region, China has seen rapid health infrastructure improvements, which extend to the management of chronic coughs. CRC treatment in Japan often involves cutting-edge technology and pharmaceuticals supported by government-backed healthcare policies. Japan's aging population also makes it a critical market for CRC management solutions. In India, the rising middle class and improvements in healthcare facilities are creating significant opportunities for CRC management.

Market Insights

  • Market Dynamics

The market dynamics represent an ever-changing landscape of the Chronic Refractory Cough Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

    • Market Drivers
      • Rising prevalence of chronic refractory cough
      • Government support for awareness and early diagnosis
    • Market Restraints
      • Potential risk of drug recall
    • Market Opportunities
      • Increasing R&D initiatives toward effective drug development
      • Collaborative drug development and improving healthcare expenditure
    • Market Challenges
      • Side effects associated CRC treatment
  • Market Segmentation Analysis
    • Drug Type: Exploring gabapentin for innovative treatments for chronic refractory cough with neuropathic links
    • Distribution Channel: Increasing preference to online pharmacies for chronic refractory cough treatment
  • Market Disruption Analysis
  • Porter's Five Forces Analysis
  • Value Chain & Critical Path Analysis
  • Pricing Analysis
  • Technology Analysis
  • Patent Analysis
  • Trade Analysis
  • Regulatory Framework Analysis

FPNV Positioning Matrix

The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Chronic Refractory Cough Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Chronic Refractory Cough Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Recent Developments

Investment Surge in Novel Respiratory Therapeutics: Focus on Nocion Therapeutics' Development of Taplucanium for Chronic Refractory Cough

Nocion Therapeutics, based in Watertown, Massachusetts, has completed a USD 62 million Series B funding round to advance the development of their innovative drug, taplucanium. Nocion is pioneering a novel approach by targeting the nociceptors-sensory neurons that trigger pain, itching, or coughs-which are implicated in various conditions including chronic refractory cough, a difficult-to-treat condition characterized by a persistent cough without a clear underlying cause [Published On: 2024-03-04]

Trevi Therapeutics Launches Phase 2a RIVER Trial for Haduvio, Advancement in Refractory Chronic Cough Treatment

Trevi Therapeutics, Inc., a pioneering company in clinical-stage biopharmaceuticals, recently initiated the Phase 2a RIVER clinical trial to assess the efficacy of Haduvio (oral nalbuphine ER) in treating patients with refractory chronic cough (RCC). The RIVER trial, a rigorous double-blind, placebo-controlled study with a 2-period crossover design, aims to enroll approximately 60 participants who suffer from moderate to severe cough frequencies [Published On: 2023-11-02]

GSK PLC Finalizes Acquisition of BELLUS Health Inc. Health to Enhance Chronic Refractory Cough Treatment Portfolio

GSK PLC has acquired BELLUS Health Inc., integrating BELLUS Health Inc.'s promising drug candidate, camlipixant, a highly selective P2X3 antagonist into its respiratory therapy lineup. Camlipixant, now in phase III trials, targets the first line treatment of adult patients with refractory chronic cough. The transaction, endorsed by BELLUS Health Inc. shareholders to leverage GSK PLC's robust R&D, manufacturing, and commercialization capabilities to expedite the drug's market launch. [Published On: 2023-06-28]

Strategy Analysis & Recommendation

The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Chronic Refractory Cough Market. This critical assessment involves a thorough analysis of the organization's resources, capabilities, and overall performance to identify its core strengths and areas for improvement.

Key Company Profiles

The report delves into recent significant developments in the Chronic Refractory Cough Market, highlighting leading vendors and their innovative profiles. These include Accord Healthcare Inc., Alitair Pharmaceuticals, Amneal Pharmaceuticals Inc., Apotex Inc., AstraZeneca PLC, Aurobindo Pharma Ltd, Bausch Health, Bayer AG, Cipla Inc., Dr Reddy's Laboratories Ltd., Glenmark Pharmaceuticals Ltd., GSK PLC, Hikma Pharmaceuticals PLC, Intas Pharmaceuticals Ltd., Mylan N.V. by Viatris Inc., NeRRe Therapeutics, Novartis AG, Pfizer Inc., Sienna Biotec, Strides Pharma, Sun Pharmaceutical Industries Ltd, Teva Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Ltd., Unichem Laboratories Ltd. by Ipca Labs, and Zydus Pharmaceuticals USA Inc..

Market Segmentation & Coverage

This research report categorizes the Chronic Refractory Cough Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Drug Type
    • Amitriptyline
    • Gabapentin
    • Pregabalin
  • Distribution Channel
    • Drug Store
    • Hospital Pharmacies
    • Online Pharmacies
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of chronic refractory cough
      • 5.1.1.2. Government support for awareness and early diagnosis
    • 5.1.2. Restraints
      • 5.1.2.1. Potential risk of drug recall
    • 5.1.3. Opportunities
      • 5.1.3.1. Increasing R&D initiatives toward effective drug development
      • 5.1.3.2. Collaborative drug development and improving healthcare expenditure
    • 5.1.4. Challenges
      • 5.1.4.1. Side effects associated CRC treatment
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Drug Type: Exploring gabapentin for innovative treatments for chronic refractory cough with neuropathic links
    • 5.2.2. Distribution Channel: Increasing preference to online pharmacies for chronic refractory cough treatment
  • 5.3. Market Disruption Analysis
  • 5.4. Porter's Five Forces Analysis
    • 5.4.1. Threat of New Entrants
    • 5.4.2. Threat of Substitutes
    • 5.4.3. Bargaining Power of Customers
    • 5.4.4. Bargaining Power of Suppliers
    • 5.4.5. Industry Rivalry
  • 5.5. Value Chain & Critical Path Analysis
  • 5.6. Pricing Analysis
  • 5.7. Technology Analysis
  • 5.8. Patent Analysis
  • 5.9. Trade Analysis
  • 5.10. Regulatory Framework Analysis

6. Chronic Refractory Cough Market, by Drug Type

  • 6.1. Introduction
  • 6.2. Amitriptyline
  • 6.3. Gabapentin
  • 6.4. Pregabalin

7. Chronic Refractory Cough Market, by Distribution Channel

  • 7.1. Introduction
  • 7.2. Drug Store
  • 7.3. Hospital Pharmacies
  • 7.4. Online Pharmacies

8. Americas Chronic Refractory Cough Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Chronic Refractory Cough Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Chronic Refractory Cough Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
    • 11.3.1. Investment Surge in Novel Respiratory Therapeutics: Focus on Nocion Therapeutics' Development of Taplucanium for Chronic Refractory Cough
    • 11.3.2. Trevi Therapeutics Launches Phase 2a RIVER Trial for Haduvio, Advancement in Refractory Chronic Cough Treatment
    • 11.3.3. GSK PLC Finalizes Acquisition of BELLUS Health Inc. Health to Enhance Chronic Refractory Cough Treatment Portfolio
  • 11.4. Strategy Analysis & Recommendation

12. Competitive Portfolio

  • 12.1. Key Company Profiles
  • 12.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. CHRONIC REFRACTORY COUGH MARKET RESEARCH PROCESS
  • FIGURE 2. CHRONIC REFRACTORY COUGH MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. CHRONIC REFRACTORY COUGH MARKET DYNAMICS
  • FIGURE 7. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. AMERICAS CHRONIC REFRACTORY COUGH MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 12. AMERICAS CHRONIC REFRACTORY COUGH MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. UNITED STATES CHRONIC REFRACTORY COUGH MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 14. UNITED STATES CHRONIC REFRACTORY COUGH MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. ASIA-PACIFIC CHRONIC REFRACTORY COUGH MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 16. ASIA-PACIFIC CHRONIC REFRACTORY COUGH MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA CHRONIC REFRACTORY COUGH MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA CHRONIC REFRACTORY COUGH MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. CHRONIC REFRACTORY COUGH MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 20. CHRONIC REFRACTORY COUGH MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. CHRONIC REFRACTORY COUGH MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY AMITRIPTYLINE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY AMITRIPTYLINE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY GABAPENTIN, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY GABAPENTIN, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY PREGABALIN, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY PREGABALIN, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG STORE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG STORE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 23. AMERICAS CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 24. AMERICAS CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 25. AMERICAS CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 26. AMERICAS CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 27. AMERICAS CHRONIC REFRACTORY COUGH MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 28. AMERICAS CHRONIC REFRACTORY COUGH MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 29. ARGENTINA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 30. ARGENTINA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 31. ARGENTINA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 32. ARGENTINA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 33. BRAZIL CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 34. BRAZIL CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 35. BRAZIL CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 36. BRAZIL CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 37. CANADA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 38. CANADA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 39. CANADA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 40. CANADA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 41. MEXICO CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 42. MEXICO CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 43. MEXICO CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 44. MEXICO CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 45. UNITED STATES CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 46. UNITED STATES CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 47. UNITED STATES CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 48. UNITED STATES CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 49. UNITED STATES CHRONIC REFRACTORY COUGH MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 50. UNITED STATES CHRONIC REFRACTORY COUGH MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 53. ASIA-PACIFIC CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 54. ASIA-PACIFIC CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 55. ASIA-PACIFIC CHRONIC REFRACTORY COUGH MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 56. ASIA-PACIFIC CHRONIC REFRACTORY COUGH MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 57. AUSTRALIA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 58. AUSTRALIA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 59. AUSTRALIA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 60. AUSTRALIA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 61. CHINA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 62. CHINA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 63. CHINA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 64. CHINA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 65. INDIA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 66. INDIA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 67. INDIA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 68. INDIA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 69. INDONESIA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 70. INDONESIA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 71. INDONESIA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 72. INDONESIA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 73. JAPAN CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 74. JAPAN CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 75. JAPAN CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 76. JAPAN CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 77. MALAYSIA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 78. MALAYSIA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 79. MALAYSIA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 80. MALAYSIA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 81. PHILIPPINES CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 82. PHILIPPINES CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 83. PHILIPPINES CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 84. PHILIPPINES CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 85. SINGAPORE CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 86. SINGAPORE CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 87. SINGAPORE CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 88. SINGAPORE CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 89. SOUTH KOREA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 90. SOUTH KOREA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 91. SOUTH KOREA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 92. SOUTH KOREA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 93. TAIWAN CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 94. TAIWAN CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 95. TAIWAN CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 96. TAIWAN CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 97. THAILAND CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 98. THAILAND CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 99. THAILAND CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 100. THAILAND CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 101. VIETNAM CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 102. VIETNAM CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 103. VIETNAM CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 104. VIETNAM CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA CHRONIC REFRACTORY COUGH MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 110. EUROPE, MIDDLE EAST & AFRICA CHRONIC REFRACTORY COUGH MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 111. DENMARK CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 112. DENMARK CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 113. DENMARK CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 114. DENMARK CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 115. EGYPT CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 116. EGYPT CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 117. EGYPT CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 118. EGYPT CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 119. FINLAND CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 120. FINLAND CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 121. FINLAND CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 122. FINLAND CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 123. FRANCE CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 124. FRANCE CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 125. FRANCE CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 126. FRANCE CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 127. GERMANY CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 128. GERMANY CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 129. GERMANY CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 130. GERMANY CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 131. ISRAEL CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 132. ISRAEL CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 133. ISRAEL CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 134. ISRAEL CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 135. ITALY CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 136. ITALY CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 137. ITALY CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 138. ITALY CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 139. NETHERLANDS CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 140. NETHERLANDS CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 141. NETHERLANDS CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 142. NETHERLANDS CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 143. NIGERIA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 144. NIGERIA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 145. NIGERIA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 146. NIGERIA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 147. NORWAY CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 148. NORWAY CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 149. NORWAY CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 150. NORWAY CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 151. POLAND CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 152. POLAND CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 153. POLAND CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 154. POLAND CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 155. QATAR CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 156. QATAR CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 157. QATAR CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 158. QATAR CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 159. RUSSIA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 160. RUSSIA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 161. RUSSIA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 162. RUSSIA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 163. SAUDI ARABIA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 164. SAUDI ARABIA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 165. SAUDI ARABIA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 166. SAUDI ARABIA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 167. SOUTH AFRICA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 168. SOUTH AFRICA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 169. SOUTH AFRICA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 170. SOUTH AFRICA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 171. SPAIN CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 172. SPAIN CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 173. SPAIN CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 174. SPAIN CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 175. SWEDEN CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 176. SWEDEN CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 177. SWEDEN CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 178. SWEDEN CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 179. SWITZERLAND CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 180. SWITZERLAND CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 181. SWITZERLAND CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 182. SWITZERLAND CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 183. TURKEY CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 184. TURKEY CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 185. TURKEY CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 186. TURKEY CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 187. UNITED ARAB EMIRATES CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 188. UNITED ARAB EMIRATES CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 189. UNITED ARAB EMIRATES CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 190. UNITED ARAB EMIRATES CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 191. UNITED KINGDOM CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 192. UNITED KINGDOM CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 193. UNITED KINGDOM CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 194. UNITED KINGDOM CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 195. CHRONIC REFRACTORY COUGH MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 196. CHRONIC REFRACTORY COUGH MARKET, FPNV POSITIONING MATRIX, 2023